Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.

@article{Coyle2001ActivityOO,
  title={Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.},
  author={Elizabeth A. Coyle and Michael Joseph Rybak},
  journal={Antimicrobial agents and chemotherapy},
  year={2001},
  volume={45 3},
  pages={
          706-9
        }
}
In the past 2 decades, multidrug-resistant Streptococcus pneumoniae has been encountered with increasing frequency around the world. This has led to the need for newer agents in the treatment of S. pneumoniae infections. Oritavancin (LY333328) is a new glycopeptide antibiotic with activity against gram-positive organisms; however, there is limited information on the pharmacodynamics of oritavancin with respect to the treatment of S. pneumoniae. We utilized an in vitro pharmacodynamic model to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates

F. G. Garrote, E. Cercenado, L. Alcala, E. Bouza
  • Antimicrob. Agents Chemother
  • 1998
VIEW 1 EXCERPT

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

Mercier, C R., H. H. Houlihan, M. J. Rybak
  • Antimicrob. Agents Chemother
  • 1997
VIEW 1 EXCERPT